Amphastar Pharmaceuticals (AMPH) Retained Earnings (2013 - 2026)

Amphastar Pharmaceuticals' Retained Earnings history runs 14 years deep, the most recent figure standing at $673.3 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 8549.0% year-over-year to $673.3 million; the TTM figure through Mar 2026 stood at $673.3 million (up 8549.0% YoY), while the FY2025 annual figure was -$5.3 million, up 42.12% from the prior year.
• Retained Earnings was $673.3 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$5.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $673.3 million in Q1 2026 to a low of -$9.9 million in Q3 2022.
• Historically, Retained Earnings has averaged $104.1 million across 5 years, with a median of -$7.2 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings slumped 106.18% in 2022, then soared 8549.0% in 2026.
• A 5-year view of Retained Earnings shows it stood at $271.7 million in 2022, then sank by 103.12% to -$8.5 million in 2023, then retreated by 8.29% to -$9.2 million in 2024, then jumped by 42.12% to -$5.3 million in 2025, then jumped by 12770.32% to $673.3 million in 2026.
• The last three Retained Earnings figures came in at $673.3 million (Q1 2026), -$5.3 million (Q4 2025), and -$5.3 million (Q3 2025), per Business Quant data.